⌕
Avis Budget Group · CAR · Nasdaq
Tenet 34 · Weak
Compare
$122.86−2.06%At closeTenet 34 · Weak
$122.86−2.59 (−2.06%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Avis Budget Group (CAR) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

● GlobeNewsWireNov 11, 2026 · 08:53 ETEARNINGS EXPECTED BY FEB 16
Tempest Therapeutics Exercises Option to License Senlang's CD7-Targeted Lentiviral In Vivo CAR-T Platform Following Initial Phase 1 Results with Lead BCMA/GPRC5D Candidate

-Tempest secures exclusive global rights outside China to a targeted lentiviral platform and portfolio of in vivo CAR-T candidates…

● Business WireNov 8, 2026 · 10:30 ET
HSS Study Highlights Potential for CAR T-Cell Therapy to Transform Lupus Treatment

ORLANDO, Fla.--(BUSINESS WIRE)--A type of cellular therapy originally developed to treat cancer is showing promise as a potential treatment for people with difficult-to-treat lupus, according to a new study from research…

● Seeking AlphaNov 6, 2026 · 22:45 ETEARNINGS EXPECTED BY FEB 16
Avis: A More Balanced Outlook After The Short Squeeze (Upgrade)

Avis Budget Group experienced a dramatic short squeeze, surging from $100 to $800 before collapsing as institutional holders exited. Pentwater Capital's exit and subsequent $650 million settlement with Avis ended the squ…

● Zacks Investment ResearchNov 6, 2026 · 11:46 ETEARNINGS EXPECTED BY FEB 16
Avis Budget Stock Appreciates 10% Despite Earnings Miss in Q3

CAR shares jump 10.2% despite a Q3 earnings miss, as record fleet utilization, improved cash flow and expectations of Q4 EBITDA recovery draw attention.…

● MarketBeatNov 6, 2026 · 03:14 ET
Lyell Immunopharma Targets Mid-2027 Pivotal Data for Lymphoma CAR-T Therapy

Lyell Immunopharma NASDAQ: LYEL expects pivotal data in mid-2027 for its lead CAR-T cell therapy, ronde-cel, as the company advances the treatment in patients with large B-cell lymphoma who have received at least two pri…

● Seeking AlphaNov 4, 2026 · 15:44 ETEARNINGS EXPECTED BY FEB 16
Avis Budget Group, Inc. (CAR) Q3 2026 Earnings Call Transcript

Avis Budget Group, Inc. ( CAR ) Q3 2026 Earnings Call November 4, 2026 8:30 AM EST Company Participants David Calabria - Treasurer & Senior VP of Corporate Finance Brian Choi - Chief Executive Officer Daniel Cunha - Exec…

● MarketBeatNov 4, 2026 · 11:15 ETEARNINGS EXPECTED BY FEB 16
What Avis Budget Group (CAR) Said on Its Q3 Earnings Call

Avis Budget Group NASDAQ: CAR reported third-quarter adjusted EBITDA of $513 million, down 8% from a year earlier and about $50 million below the company's prior expectations, as weaker travel demand in August pressured …

● PRNewsWireNov 4, 2026 · 08:35 ET
Anixa Biosciences Announces Presentation of Ovarian Cancer CAR-T Clinical Trial at ESMO Immuno-Oncology & Advanced Therapies Congress 2026

Dr. Robert Wenham, principal investigator of Anixa's Phase 1 clinical trial at Moffitt Cancer Center, to present on December 14 in London SAN JOSE, Calif., Nov. 4, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or…

● Zacks Investment ResearchNov 3, 2026 · 20:31 ETEARNINGS EXPECTED BY FEB 16
Compared to Estimates, Avis Budget (CAR) Q3 Earnings: A Look at Key Metrics

The headline numbers for Avis Budget (CAR) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the yea…

● Zacks Investment ResearchNov 3, 2026 · 18:51 ETEARNINGS EXPECTED BY FEB 16
Avis Budget Group (CAR) Misses Q3 Earnings Estimates

Avis Budget Group (CAR) came out with quarterly earnings of $5.15 per share, missing the Zacks Consensus Estimate of $8.47 per share. This compares to earnings of $10.11 per share a year ago.…

● GlobeNewsWireNov 3, 2026 · 08:00 ET
Allogene Highlights Clinical Progress and Next-Generation Innovation Across Its Off-the-Shelf CAR T Platform at SITC Annual Meeting

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for ca…

● Defense WorldNov 3, 2026 · 03:47 ETEARNINGS EXPECTED BY FEB 16
Avis Budget Group, Inc. $CAR Stock Sold by Hennessy Advisors Inc.

Hennessy Advisors Inc. decreased its stake in shares of Avis Budget Group, Inc. (NASDAQ: CAR) by 8.9% in a recent quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 49,30…

● Seeking AlphaOct 29, 2026 · 14:54 ETEARNINGS EXPECTED BY FEB 16
Cartesian: Maintaining 'Buy' On Descartes-08 MG Data Release And CAR-T Agreement

Cartesian Therapeutics maintains a 'Buy' rating, driven by advancing Descartes-08 cell therapy programs and imminent late-stage clinical catalysts. Topline results from the phase 3 AURORA study in AChR Ab+ Myasthenia Gra…

● Zacks Investment ResearchOct 27, 2026 · 11:01 ETEARNINGS EXPECTED BY FEB 16
Earnings Preview: Avis Budget Group (CAR) Q3 Earnings Expected to Decline

Avis Budget (CAR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.…

● Business WireOct 27, 2026 · 08:01 ET
Avis First Expands to London Heathrow and Paris Charles de Gaulle Airports

PARSIPPANY, N.J.--(BUSINESS WIRE)--Avis announced the expansion of Avis First to London Heathrow and Paris Charles de Gaulle airports, bringing its premium car rental service to more than 30 airport and city locations ac…

● PRNewsWireOct 26, 2026 · 08:30 ET
Anixa Biosciences Announces Completion of Treatment of Fifth Cohort in its Ovarian Cancer CAR-T Clinical Trial

First patient in fifth cohort exhibiting stable disease 90 days after treatment Multiple patients surviving more than one year, including one beyond two years, with no dose-limiting toxicities observed to date Patients i…

● GuruFocusOct 21, 2026 · 19:41 ET
Avis Budget Group Inc (CAR) Shares Fall 4.0% -- What GF Score of 72 Tells Investors

On October 21, 2026, Avis Budget Group Inc (CAR) shares fell 4.0%, bringing the current price to $98.39. This price is down significantly from its 52-week high…

● Zacks Investment ResearchOct 20, 2026 · 06:45 ET
New Strong Sell Stocks for October 20th

CAR, USAS and APC have been added to the Zacks Rank #5 (Strong Sell) List on October 20, 2026.…

● AccesswireOct 15, 2026 · 08:46 ET
Xenetic Biosciences and PeriNess Announce First Patient Dosed in Investigator-Initiated Study at Tel Aviv Sourasky University Medical Center Evaluating Systemic DNase in Combination with CAR T Cells for Large B-Cell Lymphoma

First clinical evaluation of Xenetic's systemic DNase technology as an adjunct to CAR T-cell therapy in an investigator-initiated study conducted at Tel Aviv Sourasky University Medical Center Initial efficacy data expec…

● GlobeNewsWireOct 15, 2026 · 08:00 ET
Legend Biotech Announces U.S. FDA Clearance of IND Application for LB2501, an Investigational CD19/CD20 In Vivo CAR-T Therapy

LB2501 is an off-the-shelf in vivo CAR-T therapy designed to generate dual-targeting CD19/CD20 CAR-T cells directly within the patient after a single infusion, making it the first known dual-targeting in vivo CAR-T thera…

● GlobeNewsWireOct 14, 2026 · 16:01 ET
Lakefront Announces Sale of Preclinical CAR-T Programs to Armed Cell Therapeutics

Previously announced wind-down of the legacy cell therapy activities is substantially complete  Mechelen, Belgium; October 14, 2026, 22.01 CEST; Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announced that…

● PRNewsWireOct 13, 2026 · 08:40 ET
Anixa Biosciences' Ovarian Cancer CAR-T Therapy Inventor to Deliver Keynote at Ovarian Cancer Midwest Focus Conference

Dr. Jose Conejo-Garcia will speak on immunotherapy for ovarian cancer at the November 2–3 conference SAN JOSE, Calif., Oct. 13, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a bi…

● 24/7 Wall StreetOct 6, 2026 · 14:04 ET
Hertz Rebounds 16% From a Record Low; Avis Climbs 5%, Ryder Ticks Up

Beaten-down rental stocks are bouncing while the wider transportation sector slips, and Hertz Global Holdings (NASDAQ:HTZ) is leading the rebound from the deepest hole in the group. Hertz stock is at $2.…

● PRNewsWireOct 5, 2026 · 08:15 ET
Anixa Biosciences Announces First Case of Stable Disease for Three Months in Ovarian Cancer CAR-T Clinical Trial

First patient in current dose cohort exhibited no progression of her cancer three months aftertreatment Multiple patients have survived more than one year, including one beyond two years No dose-limiting toxicities obser…

No recent releases where the company itself is speaking.

Kept in their own lane. A press release is the company talking, not reporting.

Expected by Feb 16. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

Article counts from the last market-wide feed page, across every symbol we track and not just CAR · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.